2,003 results match your criteria Journal of Crohn's and Colitis [Journal]


Systematic Analysis of the Impact of Diagnostic Delay on Bowel Damage in Paediatric Versus Adult Onset Crohn's Disease.

J Crohns Colitis 2019 Apr 19. Epub 2019 Apr 19.

Division of Paediatric Gastroenterology, Centre Hospitalier Universitaire Vaudois [CHUV] and University of Lausanne, Lausanne, Switzerland.

Background And Aims: Length of diagnostic delay is associated with bowel strictures and intestinal surgery in adult patients with Crohn's disease [CD]. Here we assessed whether diagnostic delay similarly impacts on the natural history of paediatric CD patients.

Methods: Data from the Swiss IBD Cohort Study were analysed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz065DOI Listing

Systematic review: components of a comprehensive geriatric assessment in inflammatory bowel disease - a potentially promising but often neglected risk stratification.

J Crohns Colitis 2019 Apr 19. Epub 2019 Apr 19.

Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.

Background: The population of older patients with inflammatory bowel disease (IBD) is increasing. Patient age does not fully account for poor outcomes and its clinical utility for risk stratification is limited. Comprehensive Geriatric Assessment (CGA), comprising a somatic, functional, mental and social assessment or frailty, could be a predictor tool. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz082DOI Listing

Differential miRNA expression in ileal and colonic tissues reveals an altered immunoregulatory molecular profile in individuals with Crohn's disease versus healthy subjects.

J Crohns Colitis 2019 Apr 19. Epub 2019 Apr 19.

Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, ON, Canada.

MicroRNAs (miRNAs) are key modulators of gene expression in Crohn's disease (CD) and may drive tissue-specific molecular alterations underlying CD susceptibility. In this study we analysed differential miRNA expression between CD and healthy subjects across ileal and colonic tissues. A cohort of CD and healthy control (HC) subjects was recruited and clinical data collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz076DOI Listing
April 2019
1 Read

Endoscopic Resections in Inflammatory Bowel Disease: A Multicentre European Outcomes Study.

J Crohns Colitis 2019 Apr 17. Epub 2019 Apr 17.

Department of Gastroenterology, Queen Alexandra Hospital, Southwick Hill Road, Portsmouth.

Background: Inflammatory bowel disease is associated with an increased risk of colorectal cancer, with estimates ranging from 2-18%, depending on the duration of colitis. The management of neoplasia in colitis remains controversial. Current guidelines recommend endoscopic resection if the lesion is clearly visible with distinct margins. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ecco-jcc/advance-article/doi/10.109
Publisher Site
http://dx.doi.org/10.1093/ecco-jcc/jjz075DOI Listing
April 2019
2 Reads

Long-term clinical effectiveness of ustekinumab in patients with Crohn's disease who failed biological therapies: a national cohort study.

J Crohns Colitis 2019 Apr 16. Epub 2019 Apr 16.

Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.

Background: Ustekinumab (UST) was recently approved in Europe for the treatment of moderate to severe Crohn's disease (CD). Long-term real-world data are currently scarce in CD patients previously exposed to several biologics.

Methods: This is an observational, national, retrospective multicenter study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz080DOI Listing

Cannabinoid signal transduction explains disconnect of cannabis effects in experimental and clinical colitis.

J Crohns Colitis 2019 Apr 16. Epub 2019 Apr 16.

Department of Gastroenterology and Hepatology Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz078DOI Listing

Low Golimumab Trough Levels at Week 6 are Associated with Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study.

J Crohns Colitis 2019 Apr 16. Epub 2019 Apr 16.

Faculdade de Medicina, Universidade do Porto, Porto, Portugal.

Background And Aims: Golimumab has an established exposure-response relationship in patients with ulcerative colitis (UC). However, the association of serum golimumab trough levels (TL) with objective markers of disease activity, such as endoscopic and histologic activity scores and concentration of biomarkers, remains less understood. This report describes the relationship of serum golimumab TL at the end of induction period (week 6) with clinical, endoscopic, histologic and biomarker parameters. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz071DOI Listing

A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong District of Seoul, Korea in 1986-2015.

J Crohns Colitis 2019 Apr 16. Epub 2019 Apr 16.

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Background And Aims: Although the incidence of inflammatory bowel disease (IBD) is increasing in Asia, data on long-term epidemiologic trends are limited. We performed a 30-year longitudinal study to investigate temporal trends in the epidemiology of Crohn's disease (CD) and ulcerative colitis (UC) in Seoul, Korea.

Methods: This population-based study included 1431 IBD patients (418 CD, 1013 UC) diagnosed between 1986 and 2015 in the Songpa-Kangdong district of Seoul, Korea. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz081DOI Listing
April 2019
1 Read

Long-term Multidonor Fecal Microbiota Transfer (FMT) by Oral Capsules for Active Ulcerative Colitis.

J Crohns Colitis 2019 Apr 15. Epub 2019 Apr 15.

Department of Internal Medicine IV (Gastroenterology, Hepatology and Infectious Diseases) University Hospital Jena, Jena, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz073DOI Listing

Effectiveness and safety of the switch from Remicade to CT-P13 in patients with inflammatory bowel disease.

J Crohns Colitis 2019 Apr 12. Epub 2019 Apr 12.

Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid.

Aims: To evaluate the clinical outcomes in patients with IBD after switching from Remicade to CT-P13 in comparison with patients who maintain Remicade .

Methods: Patients under Remicade who were in clinical remission with standard dosage at study entry were included. The switch cohort (SC) comprised patients who made the switch from Remicade to CT-P13, and the "non-switch" cohort (NC) patients kept under Remicade . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz070DOI Listing

Colonic Mucosal Transcriptomic Changes in Patients with Long-Duration Ulcerative Colitis Revealed Colitis-Associated Cancer Pathways.

J Crohns Colitis 2019 Jan 11. Epub 2019 Jan 11.

Gastroenterology Unit, Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.

Background And Aims: Patients with ulcerative colitis [UC] with long disease duration have a higher risk of developing colitis-associated cancer [CAC] compared with patients with short-duration UC. The aim of this study was to identify transcriptomic differences associated with the duration of UC disease.

Methods: We conducted transcriptome profiling on 32 colonic biopsies [11 long-duration UC, ≥20 years; and 21 short-duration UC, ≤5 years] using Affymetrix Human Transcriptome Array 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz002DOI Listing
January 2019

Mucosal and systemic immune profiles differ during early and late phase of the disease in patients with active ulcerative colitis.

J Crohns Colitis 2019 Apr 4. Epub 2019 Apr 4.

Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Dept of Internal Medicine and Clinical Nutrition, Gothenburg, Sweden.

Background And Aims: Alterations in the immunopathogenesis in ulcerative colitis (UC) during the disease course have been proposed. We therefore aimed to determine mucosal and systemic immune profiles in individual patients at the time of diagnosis (early disease) and after 10 years (late disease).

Methods: Patients with UC provided serum and mucosal biopsies during a flare at early and late disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz072DOI Listing
April 2019
1 Read

Variability of Faecal Calprotectin in Inflammatory Bowel Disease patients: an Observational Case-Control Study.

J Crohns Colitis 2019 Apr 4. Epub 2019 Apr 4.

Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Brussels, Belgium.

Background And Aims: Several factors have been reported to affect faecal calprotectin (FC) values, and significant variation in FC concentrations has been observed in inflammatory bowel disease (IBD) patients. We aimed to evaluate FC variability in IBD patients, and to assess the robustness of a single stool punch.

Methods: This is a single center observational case-control study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz069DOI Listing
April 2019
1 Read

Microbial Colonization in Adulthood Shapes the Intestinal Macrophage Compartment.

J Crohns Colitis 2019 Apr 1. Epub 2019 Apr 1.

Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Background And Aims: Contact with distinct microbiota early in life has been shown to educate the mucosal immune system, hence providing protection against immune-mediated diseases. However, the impact of early versus late colonization with regard to the development of the intestinal macrophage compartment has not been studied so far.

Methods: Germ-free mice were colonized with specific-pathogen-free [SPF] microbiota at the age of 5 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz036DOI Listing
April 2019
1 Read

The Microbiome in Paediatric Crohn's Disease-A Longitudinal, Prospective, 
Single-Centre Study.

J Crohns Colitis 2019 Mar 26. Epub 2019 Mar 26.

Enteric Virus group, Murdoch Children's Research Institute, Parkville, Victoria, Australia.

Background And Aims: The gut mucosa is the principal site where Crohn's disease [CD] inflammation occurs. Limited information is available about the gut mucosal microbiome during CD relapse and remission. The aim of our study was to characterize specific changes in the gut microbiome during relapse and remission in a large single-centre paediatric CD cohort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz016DOI Listing
March 2019
2 Reads

Butyrate does not protect against inflammation-induced loss of epithelial barrier function and cytokine production in primary cell monolayers from patients with ulcerative colitis.

J Crohns Colitis 2019 Mar 28. Epub 2019 Mar 28.

Department of Chronic Diseases, Metabolism & Ageing (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium.

Background And Aims: In vitro studies utilizing immortalised cancer cell lines showed that butyrate has an overall positive effect on epithelial barrier integrity, but the physiological relevance of cancer cell lines is limited. We developed epithelial monolayers from human tissue samples of patients with ulcerative colitis (UC) to assess the effect of butyrate on epithelial barrier function.

Methods: A protocol to establish monolayers from primary epithelial cells of UC patients (n=10) and non-UC controls (n=10) was optimized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz064DOI Listing
March 2019
4 Reads

High adherence to surveillance guidelines in IBD patients results in low colorectal cancer and dysplasia rates, while rates of dysplasia are low before the suggested onset of surveillance.

J Crohns Colitis 2019 Mar 28. Epub 2019 Mar 28.

Division of Gastroenterology, Department of Medicine, McGill University, Montreal QC.

Background: Patients with Crohn's disease (CD) and ulcerative colitis (UC) are at increased risk for colorectal dysplasia (CRD) and cancer (CRC). Adherence to CRC surveillance guidelines is reportedly low internationally.

Aim: To evaluate surveillance practices at the tertiary IBD Center of the McGill University Health Center (MUHC) and to determine CRD/CRC incidence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz066DOI Listing
March 2019
1 Read

The Evolution of Health Care Utilisation and Costs for Inflammatory Bowel Disease Over Ten Years.

J Crohns Colitis 2019 Mar 27. Epub 2019 Mar 27.

Institute of Social and Preventive Medicine [IUMSP], Lausanne University Hospital, Lausanne, Switzerland.

Background And Aims: Inflammatory bowel disease [IBD] places an economic strain on health systems due to expensive pharmaceutical therapy, risk of hospitalisation and surgery, and long-term monitoring. The evolving treatment guidelines advocate rapid scale-up to biologic agents in order to improve health outcomes and quality of life. This study evaluated changes in health care utilisation and expenditures for IBD in Switzerland over time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz003DOI Listing
March 2019
1 Read

DUBLIN (Degree of Ulcerative colitis Burden of Luminal INflammation) score, a simple method to quantify inflammatory burden in Ulcerative Colitis.

J Crohns Colitis 2019 Mar 26. Epub 2019 Mar 26.

Centre for Colorectal Disease, St. Vincent's University Hospital &School of Medicine University College Dublin, Ireland.

Background & Aims: Endoscopic scores of local severity do not reflect disease extent, or disease burden. The DUBLIN score is a simple bedside clinical score that estimates inflammatory burden using both disease severity and extent. As the need to personalise therapy for UC patients increases, a score to accurately assess disease burden will be of great relevance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz067DOI Listing
March 2019
1 Read
6.234 Impact Factor

Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers.

J Crohns Colitis 2019 Mar 19. Epub 2019 Mar 19.

Pfizer, Cambridge, MA, USA.

Background And Aims: To define pharmacodynamic and efficacy biomarkers in ulcerative colitis [UC] patients treated with PF-00547659, an anti-human mucosal addressin cell adhesion molecule-1 [MAdCAM-1] monoclonal antibody, in the TURANDOT study.

Methods: Transcriptome, proteome and immunohistochemistry data were generated in peripheral blood and intestinal biopsies from 357 subjects in the TURANDOT study.

Results: In peripheral blood, C-C motif chemokine receptor 9 [CCR9] gene expression demonstrated a dose-dependent increase relative to placebo, but in inflamed intestinal biopsies CCR9 gene expression decreased with increasing PF-00547659 dose. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjy217DOI Listing
March 2019
4 Reads

Is Crohn Disease the price to pay today for having survived to the Black Death?

J Crohns Colitis 2019 Mar 20. Epub 2019 Mar 20.

Research Centre on Inflammation, UMR1149 INSERM ; Université Paris Diderot, Sorbonne-Paris-Cité, Paris, France.

Background And Aims: Nucleotide Oligomerisation Domain 2 (NOD2) is a key gene of innate immunity which participates to the host defence toward pathogens. Several loss-of-function NOD2 mutations are associated with Crohn Disease (CD). Their high frequencies in populations of European ancestry suggest a model of balancing selection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz062DOI Listing
March 2019
2 Reads

The cost-effectiveness of biological therapy cycles in the management of Crohn's disease.

J Crohns Colitis 2019 Mar 20. Epub 2019 Mar 20.

Department of Gastroenterology University Hospital CHU of Liège Belgium.

Objectives: to examine the cost-effectiveness of continued treatment for patients with moderate-severe Crohn's disease in clinical remission, with a combination of anti-TNFα (infliximab) and immunomodulator therapy compared to two different withdrawal strategies (1) withdrawal of the anti-TNFα therapy, and (2) withdrawal of the immunomodulator therapy, respectively.

Material And Methods: A decision-tree model was constructed mimicking three treatment arms: (1) continued combination therapy with infliximab and immunomodulator, (2) withdrawal of infliximab, or (3) withdrawal of the immunomodulator. Relapses in each arm are managed with treatment intensification and reinstitution of the de-escalated drug according to a prespecified algorithm. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz063DOI Listing

Low-dose Methotrexate has Similar Outcomes to High-dose Methotrexate in Combination with Anti-TNF Therapy in Inflammatory Bowel Diseases.

J Crohns Colitis 2019 Mar 19. Epub 2019 Mar 19.

Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.

Background And Aims: Methotrexate [MTX] is a well-known immunomodulator in the treatment of inflammatory bowel disease [IBD] and is often combined with biologic agents. The ideal MTX dose for combination therapy has not been determined. This study aimed to investigate the effect of varying doses of MTX on efficacy and safety outcomes when used with anti-TNF agents in IBD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz020DOI Listing
March 2019
2 Reads

The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis.

J Crohns Colitis 2019 Feb 14. Epub 2019 Feb 14.

University of Michigan, Ann Arbor, MI, USA.

In order to identify the practical implications for both health care practitioners and patients in understanding differences between the results of trials assessing therapies for ulcerative colitis [UC], we reviewed clinical trials of therapies for moderate to severe UC, with a focus on trial design. Over time, patient populations in UC trials have become more refractory, reflecting that patients are failing treatment with additional and different classes of drug, including conventional therapies, immunosuppressant drugs, and anti-tumour necrosis factor therapies. Outcomes used to measure efficacy have become increasingly stringent in order to meet the expectations of patients and physicians, and the requirements of regulatory bodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz038DOI Listing
February 2019
7 Reads

Ileal Gene Expression Data from Crohn's Disease Small Bowel Resections Indicate Distinct Clinical Sub-Groups.

J Crohns Colitis 2019 Mar 16. Epub 2019 Mar 16.

F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Background And Aims: Heterogeneity in Crohn's disease (CD) provides a challenge for development of effective therapies. Our goal was to define a unique molecular signature for severe, refractory CD to enable precision therapy approaches to disease treatment and facilitate earlier intervention in complicated disease.

Methods: We analyzed clinical meta-data, genetics and transcriptomics from uninvolved ileal tissue from CD patients that underwent a single SB resection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz021DOI Listing
March 2019
3 Reads

Risk of malignant cancers in inflammatory bowel disease.

J Crohns Colitis 2019 Mar 15. Epub 2019 Mar 15.

Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.

Objectives: To explore the trends and the predictors of incident malignant cancer among patients with inflammatory bowel disease (IBD).

Methods: We identified a cohort of all patients with incident IBD in Quebec, Canada, from 1998 to 2015, using provincial administrative healthcare databases (RAMQ and Med-Echo). Annual incidence rates (IRs) of cancer were calculated using Poisson regression and were compared to the Quebec population using standardized incidence ratios (SIR). Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ecco-jcc/advance-article/doi/10.109
Publisher Site
http://dx.doi.org/10.1093/ecco-jcc/jjz058DOI Listing
March 2019
9 Reads

Role of Fecal Microbiota Transplantation for Maintenance of Remission in Patients with Ulcerative Colitis: A Pilot Study.

J Crohns Colitis 2019 Mar 11. Epub 2019 Mar 11.

Department of Gastroenterology, Dayanand Medical College & Hospital, Ludhiana, India.

Objectives: To study the role of fecal microbiota transplantation (FMT) in maintenance of remission in ulcerative colitis (UC).

Methods: In this pilot study, patients with UC in clinical remission after multi-session FMT were randomly allocated to either maintenance FMT or placebo colonoscopic infusion every 8 weeks, for 48 weeks. The standard of care (SOC) therapy was continued in all patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz060DOI Listing
March 2019
2 Reads
6.234 Impact Factor

Novel Leucocyte/Thrombocyte Apheresis for Induction of Steroid-Free Remission in Ulcerative Colitis: A Controlled Randomized Pilot Study.

J Crohns Colitis 2019 Mar 13. Epub 2019 Mar 13.

Department of Pathology, University of Cologne, Germany.

Background And Aims: In active ulcerative colitis [UC] refractory to mesalazine, escalation to either steroids or immunosuppression is common practice. The efficacy and safety of alternative escalation therapy with a novel leukocyte apheresis device were studied.

Methods: This was a prospective, randomized, controlled multicentre pilot study comparing leukocyte apheresis with prednisolone in refractory UC (disease activity index [DAI] ≥ 4 and ≤8). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz005DOI Listing
March 2019
2 Reads

Resolution of CMV Infection in the Bowel on Vedolizumab Therapy.

J Crohns Colitis 2019 Mar 12. Epub 2019 Mar 12.

Department of Oncological Gastroenterology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz033DOI Listing

Diffuse colitis cystica profunda in Crohn's disease: A potential diagnostic pitfall.

J Crohns Colitis 2019 Mar 11. Epub 2019 Mar 11.

Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz059DOI Listing

Early Initiation of Anti-Tnf is Associated with Favourable Long-Term Outcome in Crohn's Disease: 10-Year-Follow-Up Data from the Swiss IBD Cohort Study.

J Crohns Colitis 2019 Mar 7. Epub 2019 Mar 7.

Department of Gastroenterology, University Hospital Zurich (USZ) and University of Zurich, Zurich, Switzerland.

Background And Aims: The optimal timing of treatment escalation in Crohn's disease (CD) remains a challenge and very little is known about its long-term development following early versus late administration of anti-TNF antibodies. The long-term outcome of Swiss CD patients was comparatively assessed in an up to 10-year follow-up, using patients participating in the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS).

Methods: Prospectively-collected SIBDCS patient data, including disease history, baseline characteristics at enrolment and course of disease were analysed in patients with early versus late (<24 versus >=24 months after diagnosis) and no anti-TNF treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz057DOI Listing

Editorial: The time has come to integrate behavioral health services into IBD centers.

Authors:
Laurie Keefer

J Crohns Colitis 2019 Mar 9. Epub 2019 Mar 9.

Icahn School of Medicine at Mount Sinai, Division of Gastroenterology.

View Article

Download full-text PDF

Source
https://academic.oup.com/ecco-jcc/advance-article/doi/10.109
Publisher Site
http://dx.doi.org/10.1093/ecco-jcc/jjz054DOI Listing
March 2019
12 Reads

Early dose optimization of golimumab in nonresponders to induction treatment for ulcerative colitis is effective and supported by pharmacokinetic data.

J Crohns Colitis 2019 Mar 7. Epub 2019 Mar 7.

Janssen Research & Development, LLC, Spring House, PA, USA.

Background And Aims: In nonresponders to golimumab induction for ulcerative colitis, we assessed clinical response rates and golimumab serum concentrations when the 100 mg dose is used early in the course of maintenance.Methods: This post-hoc analysis of golimumab maintenance dosing (in the PURSUIT-M study) examined clinical outcomes and golimumab concentrations in early (Week 6) responders and nonresponders to induction, including subgroups based on body weight.

Results: In nonresponders to golimumab induction (assessed at Week 6), the 100 mg maintenance dose (starting at Week 6) resulted in a meaningful proportion (28. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz052DOI Listing

Use and success of In Vitro Fertilization following Restorative Proctocolectomy and Ileal Pouch-Anal Anastomosis. A nationwide 17-year cohort study.

J Crohns Colitis 2019 Mar 6. Epub 2019 Mar 6.

Department of Surgery, Section of Coloproctology, Aarhus University Hospital, Aarhus University, Aarhus, Denmark.

Background And Aims: Fertility decreases in women following restorative proctocolectomy for ulcerative colitis. The use and success of in vitro fertilization after restorative proctocolectomy for ulcerative colitis is not systematically studied.We aimed to estimate the use and success of in vitro fertilization treatment in female ulcerative colitis patients, with and without restorative proctocolectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz055DOI Listing
March 2019
3 Reads

Vitamin D Decreases Hepcidin and Inflammatory Markers in Newly Diagnosed Inflammatory Bowel Disease Pediatric Patients- A Prospective Study.

J Crohns Colitis 2019 Mar 6. Epub 2019 Mar 6.

Pediatric Gastroenterology Unit, Dana Dwek Children's Hospital, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Background And Aims: The role of hepcidin in inflammatory bowel disease (IBD) children with anemia is poorly understood. However, it has been shown that vitamin D suppresses hepcidin expression. We aimed to assess serum hepcidin levels and the effect of vitamin D treatment on those levels in newly diagnosed IBD pediatric patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz056DOI Listing
March 2019
1 Read

Fruit consumption is associated with alterations in microbial composition and lower rates of pouchitis.

J Crohns Colitis 2019 Mar 4. Epub 2019 Mar 4.

Division of Gastroenterology, Rabin Medical Center, Petah-Tikva, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Background: Patients with ulcerative colitis (UC) that undergo proctocolectomy with an ileal pouch-anal anastomosis commonly develop pouch inflammation (pouchitis). Pouchitis develops in a previously normal small intestine and may involve environmental factors. We explored whether diet and microbiota alterations contributed to the pathogenesis of pouchitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz053DOI Listing

Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study.

J Crohns Colitis 2019 03 1. Epub 2019 Mar 1.

Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.

Background: Therapeutic drug monitoring is used to optimize adalimumab therapy in patients with Crohn's disease (CD). However, the interindividual variability in drug absorption and the quantitative effect on drug clearance of antiadalimumab antibodies (AAA), measured with a drug resistant assay, is unclear.

Aim: Characterize adalimumab population pharmacokinetics (PopPK) and identify determinants of interindividual variability in patients with CD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz050DOI Listing
March 2019
1 Read

European Crohn's and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Disease.

J Crohns Colitis 2019 Mar 1. Epub 2019 Mar 1.

Gastroenterology and Hepatology Center, Zurich, Switzerland.

Patients with Inflammatory Bowel Disease increasingly use alternative and complementary therapies, for which appropriate evidence is often lacking. It is estimated that up to half of all patients with IBD use various forms of complementary and alternative medicine during some point in their disease course. Considering the frequent use of such therapies, it is crucial that physicians and patients are informed about their efficacy and safety in order to provide guidance and evidence-based advice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz051DOI Listing

Fecal microbiota dynamics and its relation with disease course in Crohn's disease.

J Crohns Colitis 2019 Feb 27. Epub 2019 Feb 27.

School of Nutrition and Translational Research in Metabolism (NUTRIM), Division Gastroenterology-Hepatology, Maastricht University Medical Center+, Maastricht, The Netherlands.

Background: Microbial shifts have been associated with disease activity in Crohn's disease (CD), but findings on specific taxa are inconsistent. This may be due to differences in applied methods and cross-sectional study designs. We prospectively examined the fecal microbiota in adult CD patients with changing or stable disease course over time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz049DOI Listing
February 2019
20 Reads

Low-dose metronidazole is associated with a decreased rate of endoscopic recurrence of Crohn's disease after ileal resection: a retrospective cohort study.

J Crohns Colitis 2019 Feb 27. Epub 2019 Feb 27.

Inflammatory Bowel Disease Center, University of Chicago Medicine.

Background & Aims: Recurrence of Crohn's disease after surgical resection and primary anastomosis is an important clinical challenge. Previous studies have demonstrated the benefit of imidazole antibiotics, but have been limited by adverse events and medication intolerance. We evaluated whether administration of low-dose metronidazole (250mg TID) for three months reduces endoscopic postoperative recurrence rates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz047DOI Listing
February 2019
1 Read

Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy.

J Crohns Colitis 2019 Feb 27. Epub 2019 Feb 27.

Universitätsklinik für Innere Medizin III, Vienna, Austria.

Background And Aims: The Observational Postmarketing Ulcerative colitis Study (OPUS) was conducted to obtain the first long-term (5 years) safety data assessing treatment with originator infliximab versus conventional therapies in patients with ulcerative colitis (UC) in real-world clinical practice.

Methods: The OPUS registry was a prospective, non-randomized, observational study that measured adverse events in 9 prespecified categories of interest in UC patients whose treatment with either originator infliximab or conventional therapy (defined as initiation or dose-increase of corticosteroids and/or immunosuppressants) was determined by their treating physician.

Results: Data for 2239 patients were available: N=1180 enrolled to conventional therapy (including N=296 who switched to originator infliximab during follow-up) and N=1059 enrolled to originator infliximab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz048DOI Listing
February 2019

Adalimumab for patients with Crohn's disease complicated by intra-abdominal abscess: a multicentre, prospective, observational cohort study.

J Crohns Colitis 2019 Jan;13(Supplement_1):S616

Beaujon University Hospital, Gastroenterology, Clichy, France.

doi:10.1093/ecco-jcc/jjy222 Abstract P528 from the 'Poster presentations' section of the main abstract book has been withdrawn and re-inserted as DOP63 in the 'Late-breaking abstracts' section. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz045DOI Listing
January 2019

Perceived Quality of Care is associated to disease activity, quality of life, work productivity and gender but not disease phenotype: a prospective study in a high-volume IBD center.

J Crohns Colitis 2019 Feb 21. Epub 2019 Feb 21.

First Department of Medicine, Semmelweis University, Budapest, Hungary.

Background And Aims: Measuring quality of care (QoC) in inflammatory bowel diseases (IBD) has become increasingly important, yet complex assessment of QoC from the patients' perspective is rare. We evaluated perceived QoC using the Quality of Care Through the Patient's Eyes - IBD (QUOTE-IBD) questionnaire, and investigated associations between QoC, disease phenotype, work productivity and health-related quality of life (HRQoL) in a high-volume IBD center.

Methods: Consecutive patients attending McGill University Health Centre (MUHC)-IBD Center completed the QUOTE-IBD, Short Inflammatory Bowel Disease Questionnaire (SIBDQ), IBD-Control and Work Productivity and Activity Impairment (WPAI) questionnaires. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz035DOI Listing
February 2019

Efficacy, tolerability and safety of low volume bowel preparations in Inflammatory Bowel Diseases: The French multicentre CLEAN study.

J Crohns Colitis 2019 Feb 13. Epub 2019 Feb 13.

Department of Gastroenterology, University Hospital of Besançon, University Bourgogne Franche-Comté, Besançon, France.

Background: Standard high-volume polyethylene glycol (PEG) bowel preparations (PEG-4L) are recommended in inflammatory bowel disease (IBD) patients for colonoscopy. However, low-volume preparations (≤ 2 L of active volume) are often used in clinical practice. The aim of the study was to evaluate efficacy, tolerability and safety of the various bowel preparations in IBD, including low-volume preparations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz040DOI Listing
February 2019

A Validated Score Assessing the Risk for an Intra-Abdominal Abscess in Patients with Crohn's Disease Presenting at the Emergency Department.

J Crohns Colitis 2019 Feb 14. Epub 2019 Feb 14.

Institute of Gastroenterology and Liver Diseases, Department of Medicine, Hadassah - Hebrew University Medical Center, Jerusalem, Israel.

Background And Aims: A majority of acutely-ill Crohn's disease (CD) patients who present to Emergency Department (ED) will undergo an abdominal CT to rule out disease complications. We aimed to generate a simple non-invasive scoring model to predict the presence of an intra-abdominal abscess in CD patients in the ED.

Methods: We performed a retrospective case control study at four Israeli hospitals from January-1 st-2010 to May-30 th-2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz043DOI Listing
February 2019
1 Read

Real-world effectiveness and safety of Vedolizumab for the treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.

J Crohns Colitis 2019 Feb 14. Epub 2019 Feb 14.

Department of Gastroenterology, Raigmore Hospital, Inverness.

Introduction: Vedolizumab is an anti-a4b7 monoclonal antibody that is licensed for the treatment of moderate to severe Crohn's disease and ulcerative colitis.

Aims: To establish the real-world efficacy and safety of vedolizumab in the treatment of inflammatory bowel disease.

Methods: Retrospective study involving six NHS health boards in Scotland between June 2015 and November 2017. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ecco-jcc/advance-article/doi/10.109
Publisher Site
http://dx.doi.org/10.1093/ecco-jcc/jjz042DOI Listing
February 2019
1 Read

Health Care Transition Outcomes in Inflammatory Bowel Disease: a Multinational Delphi Study.

J Crohns Colitis 2019 02 14. Epub 2019 Feb 14.

Department of Paediatric Gastroenterology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.

Background: Transition programs are designed to prepare adolescent Inflammatory Bowel Disease (IBD) patients for transfer to adult care. It is still unclear which outcome parameters define "successful transition". Therefore, this study aimed to identify outcomes important for success of transition in IBD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz044DOI Listing
February 2019
1 Read